Trump Approves Plan to Dismiss FDA Commissioner After Vape Flavor Approval

*TL;DR: President Trump has signed a plan to remove FDA Commissioner Marty Makary after the agency approved three flavored vape products under presidential pressure.

Context President Trump announced a decision to fire FDA Commissioner Marty Makary, a move reported by multiple news outlets. The administration has not yet named an acting director, leaving the agency’s leadership in flux.

Key Facts - Makary faced criticism from the White House for delaying approval of menthol, mango and blueberry vape flavors produced by Los Angeles‑based Glas. - After a weekend scolding, the FDA granted clearance for the three flavors on Tuesday. - The decision to fire Makary follows a year of controversy at the FDA, including disputes over vaccine authorizations, gene‑therapy approvals and the regulation of abortion‑pill distribution. - Health agencies under the Trump administration are experiencing a wave of vacancies: the CDC (Centers for Disease Control and Prevention) operates without a director, and the surgeon‑general post remains empty. - The Health Secretary, Robert F. Kennedy Jr., has been labeled anti‑vaccine, and his tenure has seen senior officials at the FDA, CDC and NIH (National Institutes of Health) depart.

What It Means Removing Makary could deepen leadership gaps in the nation’s primary health regulator at a time when the agency is under scrutiny for its stance on vaping products. The approval of flavored vapes, which public‑health officials warn may attract youth, signals a shift toward the administration’s “save vaping” agenda. With the CDC director seat vacant and no surgeon‑general, the broader health‑policy apparatus lacks senior guidance, potentially affecting responses to emerging health threats.

The next steps will hinge on who, if anyone, the White House appoints as acting FDA head and whether the agency will continue to fast‑track flavored vape products. Watch for announcements on interim leadership and any further regulatory changes affecting tobacco‑related products.